FDA Grants Priority Review to Sarclisa for Multiple Myeloma

Sarclisa was granted a priority review by the Food and Drug Administration for patients newly diagnosed with multiple myeloma who are ineligible for blood transplants.

Related Keywords

United States , American , Dietmar Berger , Drug Administration , American Society Of Clinical Oncology , National Cancer Institute , Clinical Oncology , Annual Meeting , Study Shows Complete Response , Patients With Multiple ,